Current Report Filing (8-k)
October 25 2022 - 8:31AM
Edgar (US Regulatory)
0001446159
false
0001446159
2022-10-19
2022-10-19
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October
19, 2022
Predictive Oncology Inc.
(Exact name of Registrant as Specified in its Charter)
Delaware |
001-36790 |
33-1007393 |
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
2915 Commers Drive, Suite 900
Eagan, Minnesota |
55121 |
(Address of Principal Executive Offices) |
(Zip Code) |
Registrant’s telephone number, including area code: (651) 389-4800
Former Name or Former Address, if Changed Since Last Report: Not Applicable
Check the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Common stock, $0.01 par value |
POAI |
Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers. |
Effective October 19, 2022, the Board of Directors
(“Board”) of Predictive Oncology Inc. (the “Company”) elected David S. Smith, JD, to the Board as a Class III
director. Mr Smith was appointed to fill the vacancy created by the resignation of Christina Jenkins, M.D. in August 2022. As a Class
III Director, Mr. Smith’s term will expire at the 2024 annual meeting of the Company’s stockholders.
Mr. Smith is a life sciences and corporate attorney,
veteran biotech industry executive and leading authority on the legal issues surrounding the therapeutic use of human tissue and cells.
Mr. Smith has extensive transactional experience, including venture financings and regulatory matters for life sciences companies and
investors. Mr. Smith frequently speaks on matters related to the commercial development of tissue, cell and stem cell technologies, and
has authored extensively on topics such as human tissue therapies and tissue engineering research. Mr. Smith currently serves on the Board
of Directors of Foundation for Cell and Gene Medicine and is a Fellow and past member of the executive committee of Tissue Engineering
and Regenerative Medicine International Society. Mr Smith was previously a member of the Board of Directors of the Pennsylvania Biotechnology
Association and past officer of the Pittsburgh Tissue Engineering Initiative.
In connection with Mr. Smith’s appointment to
the Board and in recognition of the services he will provide to the Company as a director, the Company will grant to Mr. Smith shares
of common stock from the Company’s Amended and Restated 2012 Stock Incentive Plan having a grant date value equal to $5,000.
A press release announcing the appointment of the new
director is attached hereto as Exhibit 99.1.
|
Item 9.01 |
Financial Statements and Exhibits. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange
Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
PREDICTIVE ONCOLOGY inc. |
|
|
By: |
/s/ Bob Myers |
|
|
|
Name: Bob Myers
|
|
|
|
Title: Chief Financial Officer |
|
Date: October 25, 2022
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Apr 2023 to Apr 2024